论文部分内容阅读
目的 探讨替尼泊甙 (teniposide ,VM 2 6 )这一鬼臼毒植物碱类化疗药物对口腔鳞癌的体外抗瘤效果 ,为其治疗口腔鳞癌提供实验依据。方法 有 81例纳入研究的患者 ,切取经病理证实的口腔鳞癌术后标本或活检标本行体外药敏检测。检测VM 2 6时以顺铂 (cisplatin ,CDDP)作对照 ,药物应用 5倍的峰血浆浓度。VM 2 6终浓度为 6 0mg/L ,CDDP为 15mg/L。结果 81例标本完成药敏检测 75例 ,药敏检测成功率为 92 .6 %。 75例患者按UICC标准的TNM分期结果为 :I期 2例 ,II期 11例 ,III期 34例 ,IV2 8例。这组患者病理分级结果为I级 18例 ,I～II级 37例 ,III级 2 0例。VM 2 6和CDDP对口腔鳞癌细胞的生长抑制率分别为 6 3.34%和 2 4 .0 8%,前者生长抑制率明显高于后者 (P <0 .0 1)。结论 VM 2 6对口腔鳞癌的抗瘤敏感性明显高于CDDP ,VM 2 6有望成为治疗口腔鳞癌的首选化疗药物。
Objective To investigate the in vitro anti-tumor effect of teniposide (VM 2 6), an alkaloid chemotherapeutic drug of podophyllotoxin, on oral squamous cell carcinoma and to provide experimental evidence for the treatment of oral squamous cell carcinoma. Methods Totally 81 patients were enrolled in the study. The pathological specimens of oral squamous cell carcinoma or biopsy specimens were obtained and tested in vitro. When VM 2 6 was used as a control, cisplatin (CDDP) was used as a control, and the drug was applied at 5-fold peak plasma concentration. VM 2 6 final concentration of 60mg / L, CDDP 15mg / L. Results 81 cases completed drug sensitivity test in 75 cases, drug susceptibility test success rate was 92.6%. According to the UICC standard TNM staging results, 75 patients were stage I in 2 cases, stage II in 11 cases, stage III in 34 cases and IV2 in 8 cases. The pathological grading results of this group were 18 cases of grade I, 37 cases of grade I ~ II and 20 cases of grade III. The growth inhibition rates of VM 2 6 and CDDP on oral squamous cell carcinoma were 6 3.34% and 24.08%, respectively. The growth inhibition rate of VM 2 6 and CDDP was significantly higher than that of the latter (P <0.01). Conclusion The anti-tumor sensitivity of VM 2 6 to oral squamous cell carcinoma is significantly higher than that of CDDP, and VM 2 6 is expected to be the first choice chemotherapy for oral squamous cell carcinoma.